Amgen is adding Dark Blue to its tapestry, embedding the U.K. biotech’s preclinical blood cancer program into its ...

Amgen is getting down with Disco Pharmaceuticals, commissioning the German outfit to work on cancer therapies focused on a ...

The deal hands Amgen a drug that destroys two proteins known to drive certain types of acute myeloid leukemia, a profile that ...

The acquisition is centered on Dark Blue Therapeutics' small-molecule degrader of the MLLT1 and MLLT3 proteins, which is ...

According to Citi analysts, Amgen’s acquisition of Dark Blue could further drive the strength of Amgen’s early oncology ...

Amgen has bought cancer biotech Dark Blue Therapeutics in a deal that could be worth as much as $840mn, marking the latest ...

A rendering of Amgen's new science and innovation center in Thousand Oaks. (courtesy photo) Thousand Oaks-based Amgen started the new year with excitement by adding to its robust oncology pipeline.

Dark Blue Therapeutics ("Dark Blue"), a discovery and development biotech company pioneering the next generation of precision oncology medicines, has been acquired by Amgen (NASDAQ: AMGN).

Amgen is committed to reducing drug costs, expanding its AmgenNow program, and investing in US manufacturing to gain tariff ...

Amgen (NASDAQ:AMGN) remains a major biotechnology name as nasdaq composite discussions highlight healthcare innovation.

If you are wondering whether Amgen's current share price still offers value after a strong run, this article walks through ...

Biotech Amgen will grow its oncology treatment options with the acquistion of UK-based Dark Blue Therapeutics.